Phase 1 and Other Cancers

The following list provides a brief description of Phase 1 and other cancer trials that are open for recruitment in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.

Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.

Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.

 

20190136

Registered Title   A Phase 1, Multicenter, Open-label, Dose Exploration and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 994 Monotherapy and Combination of AMG 994 and AMG 404 in Subjects With Advanced Solid Tumors
Purpose   The primary objective of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD)/maximum tolerated combination dose (MTCD) or recommended phase 2 dose (RP2D) of AMG 994 as monotherapy and AMG 994 in combination with AMG 404 in participants with advanced solid tumors.
Lay Summary N/A
WA Trial Sites   Ph. 08 6382 5513
Links US National Library of Medicine 

Acknowledgements: US National Library of Medicine

 

MoST 10

Registered Title   Single arm, open label, signal seeking, phase II trial of the activity of Palbociclib in combination with Avelumab in patients with tumours with amplified D-type cyclins or CDK4/6 or inactivation of CDKN2A.
Purpose This is a substudy of the Cancer Molecular Screening and Therapeutics (MoST) Program, which is registered on ANZCTR with ID ACTRN12616000908437. This substudy will evaluate the activity of combination of palbociclib and avelumab after initial priming with palbociclib in patients with advanced cancer with eligible mutations of the following:
1. Gain-of function mutations in CDK4 and CCND1-3
2. CDKN2A deletion or loss-of-function mutations
Lay Summary   N/A
WA Trial Sites    Ph. 08 6382 5513
 Links Australian New Zealand Clinical Trials Registry 

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

MosT 7

Registered Title   Single arm, open label, signal seeking, phase IIa trial of the activity of Tremelimumab in patients with advanced rare or neglected cancers.
Purpose This study will determine if an immunotherapy drug (called tremelimumab) has an effect on progression-free survival in patients with rare or neglected cancers. This is a substudy of the Cancer Molecular Screening and Therapeutics (MoST) Program.
Lay Summary Participants will receive the study drug (Tremelimumab) via intravenous infusion every 4 weeks for 6 cycles.  Participants will complete imaging, clinical and safety assessments throughout the study.   It is hoped that tremelimumab will be well tolerated and will improve outcomes for future patients, however, there may be no clear benefit from participation in this study.
WA Trial Sites   Ph. 08 6382 5513
 Links Australian New Zealand Clinical Trials Registry

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

VT3989-001

Registered Title  Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of VT3989 in Patients With Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the NF2 Gene 
Purpose   This is an open-label, dose escalation and expansion study to evaluate the safety,
tolerability, PK, and biological activity of VT3989 administered once-daily in patients with
advanced pleural malignant mesothelioma and/or metastatic solid tumors that are resistant or
refractory to standard therapy or for which no effective standard therapy is available.
Lay Summary   N/A
WA Trial Sites    Ph. 08 6382 5513
Links  US National Library of Medicine 

Acknowledgements: US National Library of Medicine

 

GO42144

Registered Title  A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation 
Purpose   This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety,
pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or
metastatic solid tumors with a KRAS G12C mutation.
Lay Summary   N/A
WA Trial Sites    Ph. 08 6382 5513
Links   US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

WMS1030-101

Registered Title   A Phase I, Open-label, Multicenter, Dose-escalation and Dose-expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of WM-S1-030 in Patients With Advanced Solid Tumors
Purpose  his study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and
efficacy of WM-S1-030 in patients with advanced solid tumors.
Lay Summary   This is a Phase I, open-label, multicenter, dose-escalation, and dose-expansion study of WM-S1-030 in patients with advanced or metastatic solid tumors. The study will be conducted in 2 parts; a dose-escalation phase (Part 1) and a dose-expansion phase (Part 2). Part 1 will investigate oral administration of WM-S1-030 as monotherapy. Once the MTD or recommended dose is identified in Part 1, additional patients will be enrolled into Part 2 to further investigate efficacy, safety, PK, pharmacodynamics, dosing interval or schedule, and food effect on the single-dose PK of WM-S1-030.
WA Trial Sites     Ph. 08 6382 5513
Links   US National Library of Medicine 

Acknowledgements: US National Library of Medicine

 

SBT6050-101

Registered Title   A Phase 1/1B, Open-Label, Dose Escalation and Expansion Study of SBT6050 Alone and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Expressing HER2
Purpose  A first-in-human (FIH) study using SBT6050 and SBT6050 in combination with pembrolizumab in HER2 expressing or amplified advanced malignancies.
Lay Summary   N/A
WA Trial Sites   Ph. (08) 6500 5555
 Links US National Library of Medicine 

Acknowledgements: US National Library of Medicine

 

BGB-A317-15025-101

Registered Title  A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Purpose  The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors.  
Lay Summary   N/A
WA Trial Sites   Ph. 08 6382 5513
 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

FLAGSHP-1 / ERAS-601-01

Registered Title  FLAGSHP-1: An Open-Label, Multi-Center Phase 1/1b Dose Escalation and Expansion Study of ERAS-601 SHP2 Inhibitor as a Monotherapy and in Combination With a MEK Inhibitor in Patients With Advanced or Metastatic Solid Tumors 
Purpose  To evaluate the safety and tolerability of ERAS-601.

To determine the ERAS-601 Maximum Tolerated Dose (MTD) and/or recommended dose (RD) as a monotherapy and in combination with a MEK inhibitor.
To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a monotherapy and in combination with a MEK inhibitor.

Lay Summary   N/A
WA Trial Sites   Ph. 08 6382 5513
Links   US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

MoST 6

Scientific Title   Single arm, open label, signal seeking, phase IIa trial of the activity of larotrectinib in patients with advanced NTRK1-3 positive tumours
Purpose The aim of MoST substudies 14 - 15 is to assess the clinical activity of larotrectinib in patients with advanced (rare) solid cancers harbouring NTRK 1-3 rearrangements/fusions into two groups:
Group 1: primary central nervous system (CNS) cancers
Group 2: non-CNS cancers.
Primary and secondary objectives are per framework with one substudy specific objective below.
Secondary objectives -Progression free survival at 6 months.
Lay Summary  N/A
WA Trial Sites   Ph. 08 6382 5513
Links  Australian New Zealand Clinical Trials Registry 

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

INCB99280-112

Registered Title  A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Select Advanced Solid Tumors
Purpose  The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics,
pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid
tumors
Lay Summary   N/A
WA Trial Sites  Ph. 08 6382 5513
Links  US National Library of Medicine 

Acknowledgements: US National Library of Medicine

 

MoST 8

Registered Title   Single arm, open label, signal seeking, phase IIa trial of the activity of Trastuzumab emtansine (T-DM1) in patients with tumours harbouring HER2 amplifications or mutations
Purpose
Lay Summary   Participants will continue to receive T-DM1 intravenously at a dose of 3.6 mg/kg every 21 days continuously as long as they and their doctor agree there is a benefit from treatment. Participants will undergo imaging assessments at 9 weekly intervals or as clinically indicated in order to evaluate tumour response. Safety and tolerability of treatment and health related quality of life during treatment will be assessed at 3 weekly intervals.
WA Trial Sites   Ph. 08 6382 5513
 Links Australian New Zealand Clinical Trials Registry 

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

MoST - Cancer Molecular Screening and Therapeutics

Registered Title  The Cancer Molecular Screening and Therapeutics (MoST) Program - A framework protocol for multiple, parallel, signal-seeking clinical studies of novel molecularly targeted therapies for patients with advanced cancer and unmet clinical need.
Purpose This study aims to screen patients with advanced cancer and unmet clinical needs for actionable biomarkers to be used to guide therapy.
Who is it for? You may be eligible to join this study if you are aged 18 years and older, with pathologically confirmed advanced and/or metastatic rare cancer or a less common cancer or an earlier diagnosis of a poor prognosis cancer and have received all standard anticancer therapy. 
Lay Summary  A small part of your tumour tissue, which was collected from a previous biopsy or surgery, will be used to identify a biomarker by doing a laboratory analysis (‘molecular screening'). The screening includes genetic panel testing, which means looking for changes in a subset of genes (DNA) in your tumour tissue and other laboratory assays. You will be asked to provide information about your and your family's health background, to donate a blood sample and complete some questionnaires.
WA Trial Sites   Ph. 08 6382 5513
Links  Australian New Zealand Clinical Trials Registry 

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

MK-3475-587/KEYNOTE-587

Registered Title  A Multicenter, Open Label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial
Purpose  The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab
(MK-3475) in participants from previous Merck pembrolizumab-based parent studies who
roll-over into this extension study. 
Lay Summary   N/A
WA Trial Sites    Ph.(08)6465 9204
Links   US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

AK104-101

Registered Title  A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors 
Purpose This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK104 as a single agent in adult subjects with advanced solid tumor malignancies. The study consists of a dose escalation phase (Phase 1a) to determine the maximum tolerated dose (MTD), or recommended Phase 2 dose (RP2D) for AK104 as a single agent, and a dose expansion phase (Phase 1b) which will characterize treatment of AK104 as a single agent at the MTD or RP2D. 
Lay Summary   N/A
WA Trial Sites  Ph. 08 6382 5513
 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

NAVIGATE

Registered Title  A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors
Purpose  This research study is done to test how well different types of cancer respond to the drug
called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or
NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells
and can therefore be used to treat cancer.
Lay Summary  N/A
WA Trial Sites  Medical Oncology Ph. (08) 6383 3000
Links US National Library of Medicine 
Acknowledgements: US National Library of Medicine

 

PMR-116-101

Registered Title  Investigating the safety and tolerability of PMR-116 in Patients with Advanced Malignancies
Purpose This is an open-label multiple ascending dose study to assess the safety and tolerability of PMR-116, a drug treatment for patients with advanced solid tumours of any cancer type.
Lay Summary  N/A
WA Trial Sites  Ph. 08 6382 5513
Links Australian New Zealand Clinical Trials Registry 
Acknowledgements: Australian New Zealand Clinical Trials Registry

 

D1553-101 

Registered Title  A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation
Purpose  This is a phase 1/2, open label study of D-1553 single agent and combination treatment to assess the safety and tolerability, identify the MTD and RP2D, evaluate the PK properties and antitumor activities in subjects with advanced or metastatic solid tumor with KRasG12C mutation.
Lay Summary  N/A
WA Trial Site  Oncology Clinical Trials Unit - Ph. (08) 9428 8556
Links US National Library of Medicine 
Acknowledgements: US National Library of Medicine

 

CA022-001

Registered Title Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors
Purpose  The purpose of this study is to determine whether a Monoclonal Antibody both by itself and in
combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors.
Lay Summary  N/A
WA Trial Site   Oncology Clinical Trials Unit - Ph. (08) 9428 8556
Purpose  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

EMBRACE

Registered Title Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2: The EMBRACE study
Purpose This study is testing olaparib, in Homologous recombination (HR) deficient metastatic breast and relapsed ovarian cancer in patients who do not have hereditary mutations in BReast CAncer susceptibility gene 1 and gene 2 (BRCA1 and BRCA2).
Lay Summary  N/A
WA Trial Sites  (Oncology) Ph. 08 615 26530
Links  Australian New Zealand Clinical Trials Registry

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

MOST Substudy 1

Registered Title MoST Substudy 1: Single arm, open label, signal seeking, phase Ib/IIa trial of the CDK4/6 inhibitor palbociclib in patients with tumours with amplified D-type cyclins or CDK4 or inactivation of CDKN2A.
Purpose This is a substudy of the Cancer Molecular Screening and Therapeutics (MoST) Program, which is registered on ANZCTR with ID ACTRN12616000908437. This substudy will evaluate the activity of palbociclib in patients with advanced cancers and tumours with mutations in components of the Rb-pathway.
Lay Summary  N/A
WA Trial Sites  ph. 08 6382 5513
Links  Australian New Zealand Clinical Trials Registry

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

BGB-283/PD-0325901-AU-001

Registered Title A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors
Purpose  This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 combination in
patients with tumors.
Lay Summary  N/A
WA Trial Sites  ph. 08 6382 5513
Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

M19-037

Registered Title A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Combinations of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Subjects With Locally Advanced or Metastatic Solid Tumors
Purpose  A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.
Lay Summary  N/A
WA Trial Sites  (08) 9242 7640
Links US National Library of Medicine 
Acknowledgements: US National Library of Medicine

 

RAGNAR  42756493CAN2002

Registered Title  A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations
Purpose  The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in participants with advanced solid tumors with fibroblast growth factor receptor (FGFR) mutations and gene fusions.
Lay Summary  N/A
WA Trial Sites  Cancer Centre Clinical Trials Unit Ph. 08 615 26530
Links US National Library of Medicine 
Acknowledgements: US National Library of Medicine

 

YH003002

Registered Title  A Multicenter, Open-Label, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of YH003 in combination with Toripalimab (anti-PD-1 mAb) in Subjects with Advanced Solid Tumors
Purpose The main purposes of this study are to assess the safety, tolerability, preliminary efficacy and PK of YH003 in combination with anit-PD-1 mAb Toripalimab in subjects with advanced solid tumors in dose escalation and to explore the preliminary efficacy of YH003 in combination with Toripalimab with or without chemotherapy in subjects with unresectable metastatic melanoma and pancreatic ductal adenocarcinoma in the cohort expansion.
Lay Summary  N/A
WA Trial Sites  Linear Clinical Research ph. 08 6382 5513
 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

EVX-02-001

Registered Title  A Phase 1/2, Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 After Complete Resection of Stage IIIB/IIIC/IIID or Stage IV Melanoma in Patients at High Risk for Recurrence.
Purpose  This is a Phase 1/2, open label, multi-centre study to assess the safety, tolerability, PD,
and efficacy of adjuvant immunotherapy EVX-02 vaccine and anti-PD-1 (Nivolumab) in patients
who have had a complete resection of a Stage IIIB/IIIC/IIID or Stage IV melanoma who are at
high risk of recurrence.
Lay Summary  N/A
WA Trial Sites Linear Clinical Research ph. 08 6382 5513 
Links US National Library of Medicine 
Acknowledgements: US National Library of Medicine

 

SHR-1701-001AUS

Registered Title A Phase 1, Open-Label, Multi-Center, Non-Randomized, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SHR-1701 in Subjects With Advanced Solid Tumors.
Purpose  This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and
tolerability of SHR-1701 in subjects with advanced solid tumors.
Lay Summary This is a two-part, open-label, multicenter, non-randomized, dose escalation, Phase 1 study of repeated doses of SHR-1701 in subjects with advanced solid tumors who have failed current standard anti-tumor therapies.
WA Trial Sites  Linear Clinical Research ph. 08 6382 5513
Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

AIS B01

Registered Title An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)
Purpose  This is a cohort-based, open-label dose escalation and expansion study in adults with
advanced solid tumors or lymphoma, refractory or resistant to standard therapy, or without
available standard or curative therapy.
Lay Summary  N/A
WA Trial Sites  Linear Clinical Research ph. 08 6382 5513
Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

CS1001

Registered Title A Phase Ib/II, Multicenter Open-label Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid Tumors
Purpose  This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment
effect of CS1001 in combination with regorafenib in patients with advanced or refractory
cancers.
Lay Summary  N/A
WA Trial Sites  Ph. (08) 6465 9204
Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

R3767-ONC-1613

Registered Title  A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies.
Purpose The primary objectives in the dose escalation phase are to evaluate safety and
pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of
REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced
malignancies, including lymphoma.

The primary objectives in the dose expansion phase are to assess preliminary anti-tumor
activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as
measured by objective response rate (ORR)."

Lay Summary  N/A
WA Trial SItes  SCGH Medical Oncology Ph. (08) 6383 3000
Links US National Library of Medicine 
Acknowledgements: US National Library of Medicine

 

MoST Addendum 4

Registered Title Single arm, open label, signal seeking, phase IIa trial of the activity of vismodegib in patients with tumours harbouring PTCH1 or SMO mutations
Purpose This is a substudy of the Cancer Molecular Screening and Therapeutics (MoST) Program, which is registered on ANZCTR with ID ACTRN12616000908437. This substudy will evaluate the activity of vismodegib in patients with advanced cancers and tumours.
Lay Summary  You may be eligible to join the study if you are aged 18 years and older, with pathologically confirmed advanced and/or metastatic solid cancer of any cell type or an earlier diagnosis of a poor prognosis cancer and have received all standard anticancer therapy. Participants will have tumours with mutations in PTCH1 or SMO.
WA Trial Sites  Linear Clinical Research ph. 08 6382 5513
Links  Australian New Zealand Clinical Trials Registry

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

CA224-048

Registered Title A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors 
Purpose  The purpose of this study is to investigate safety and anti-tumor activity of relatlimab combination therapy in solid cancers that are advanced or have spread
Lay Summary  N/A
WA Trial Sites

 Linear Clinical Research ph. 08 6382 5513

 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

ABN401-001

Registered Title A Phase 1-2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors
Purpose This is a dose escalation, Phase 1-2 study of ABN401 in patients with advanced solid tumors,refractory metastatic disease, or refractory locally advanced disease not amenable to local therapy.
Lay Summary  N/A
WA Trial Sites  Linear Clinical Research ph. 08 6382 5513
Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

IN10018-004-01

Registered Title A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic Melanoma
Purpose  This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and
antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in
subjects with metastatic uveal melanoma and NRAS-mutant metastatic melanoma.
Lay Summary  N/A
WA Trial Sites  Linear Clinical Research ph. 08 6382 5513
Links US National Library of Medicine
Acknowledgements: US National Library of Medicine

 

BGB-A317-A445-101

Registered Title  Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Purpose  This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and
antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in
subjects with metastatic uveal melanoma and NRAS-mutant metastatic melanoma.
Lay Summary  N/A
WA Trial Sites 

 Linear Clinical Research ph. 08 6382 5513

Links  US National Library of Medicine
Acknowledgements: US National Library of Medicine

 

Maxinovel-10181-001

Registered Title A Phase I Study of MAX-10181 Given Orally to Patients With Advanced Solid Tumor
Purpose  This is a multi-center, first-in-human, non-randomized, open-label, single-arm,
dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in
patients with advanced solid tumor.
Lay Summary  N/A
WA Trial Sites  Linear Clinical Research ph. 08 6382 5513
Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

BGB-900-105

Registered Title Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Purpose  BGB-A1217 is a humanized, IgG1 monoclonal antibody against TIGIT. Tislelizumab is a
humanized, IgG4-variant monoclonal antibody against PD-1. This study tests the safety and
anti-tumor effect of BGB-A1217 in combination with tislelizumab in patients with advanced
solid tumors.
Lay Summary N.A
WA Trial Sites

 Linear Clinical Research ph. 08 6382 5513

Links  US National Library of Medicine
Acknowledgements: US National Library of Medicine

 

THOR-707-101

Registered Title  An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and in Combination With a Checkpoint Inhibitor in Adult Subjects With Advanced or Metastatic Solid Tumors
Purpose This is an open-label, First-in-Human, dose escalation and dose expansion study of THOR-707
(Monotherapy and Combination Therapy) in adult subjects with advanced or metastatic solid
tumors.
Lay Summary  N/A
WA Trial Sites  Ph. (08) 6465 9204
Links US National Library of Medicine 
Acknowledgements: US National Library of Medicine

 

MK-7339-002 / LYNK-002

Registered Title A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer
Purpose This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in
participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1)
have progressed or been intolerant to standard of care therapy; and 2) are positive for
homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).
Lay Summary  N/A
WA Trial Sites

 Linear Clinical Research ph. 08 6382 5513

LInks  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

AM-ATX101-01

Registered Title A phase 1 dose escalating study to determine incidence of dose limiting toxicities of single agent ATX-101 given by intravenous infusion every week in patients with advanced solid tumours
Purpose This is a Phase I, open-label, single arm, safety and tolerability study which will evaluate escalating dose cohorts of ATX-101 to determine the maximum tolerated dose in subjects with advanced solid tumours.
Lay Summary  N/A
WA Trial Sites

Linear Clinical Research Ph. 08 6382 5513

Links  Australian New Zealand Clinical Trials Registry

Acknowledgements: Australian New Zealand Clinical Trials Registry

 

[Return to List of Clinical Trials]